Contrive Datum Insights has published "E Prescribing Market Size, Share & Industry Analysis, By Product (Solutions, Integrated Solutions, Standalone Solutions, Services, Support, Implementation, Training, Network), Usage methods (Handheld, Computer Based Devices, Others), End-use (Hospital, Office-based Physicians, Pharmacy, Others), Substances (Controlled Substances, Non-controlled Substances, Others), Specialties (Oncology, Sports Medicine, Neurology, Cardiology, Others), and Regional Forecast, 2026-2034". The study sizes the global e prescribing market at USD 4.8 billion in 2025 and projects growth from USD 5.55 billion in 2026 to USD 16.55 billion by 2034, a compound annual growth rate of 14.64% across the forecast period.
Electronic prescribing systems let a prescriber generate, route and manage prescription orders digitally rather than on paper, connecting directly to pharmacy, insurance and clinical records systems at the point of care. The category covers the software platforms and integration services themselves, along with the implementation, training and ongoing support work needed to put them into clinical use. Buyers range from hospitals and large physician groups selecting EHR-integrated modules to individual pharmacies and specialty practices adopting standalone or handheld prescribing tools.
Regulatory mandates for electronic prescribing of controlled substances (EPCS)
Regulatory mandates for electronic prescribing of controlled substances (EPCS) is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 14.64% a year, the product lines exposed to it move fastest: Integrated Solutions compounds at 18.23%, taking its share of revenue from 18% to 24% and its value from USD 0.86 billion to USD 3.97 billion.
On the upside, the study's bull case assumes the bull case assumes EPCS mandate rollout accelerates across the remaining states faster than currently scheduled and EHR vendors bundle e-prescribing modules into standard contracts sooner, pulling integrated-solution adoption forward, which would take 2034 revenue to USD 18.21 billion against the USD 16.55 billion base case.
On the downside, the bear case assumes mandate rollout stalls in several large states and hospital IT budgets prioritize other interoperability projects ahead of e-prescribing upgrades, slowing the shift away from standalone tools, which would hold 2034 revenue to USD 14.9 billion. Solutions, which carries 22% of 2025 revenue, already grows at only 12.78% against the market's 14.64%, so the largest part of the base is also its slowest.
Where the Competition Actually Sits
Two positions matter, and they are set by product. Solutions carries 22% of 2025 revenue (USD 1.06 billion) and is still the largest line in 2034 at 19%, hard to take from an incumbent. Integrated Solutions, at 18.23%, is where the USD 4.8 billion base is redistributed. The two demand different capabilities.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Usage methods | Computer Based Devices | 55% · USD 2.64 billion | Handheld 18% |
| End-use | Hospital | 38% · USD 1.82 billion | Pharmacy 17.8% |
| Substances | Non-controlled Substances | 62% · USD 2.98 billion | Controlled Substances 17.8% |
| Specialties | Others | 44% · USD 2.11 billion | Sports Medicine 16.4% |
- Regionally, the lead sits with North America: 42% of 2025 global revenue, USD 2.02 billion rising to USD 6.12 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 21% in 2025 to 27% in 2034, with revenue growing from USD 1.01 billion to USD 4.47 billion.
- Middle East and Africa stays the smallest contributor across the period: 4% of revenue in 2025 and 4% in 2034.
- By product, the largest line in 2025 was Solutions, at 22% of revenue and USD 1.06 billion.
- No product line grows faster than Integrated Solutions, at a projected 18.23%.
- The United States is the largest single country market at USD 1.71 billion in 2025, 35.63% of global revenue.
The report segments the market across five axes; by product, and by usage methods, end-use, substances and specialties; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 14.9 billion and USD 18.21 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.